DIABETES WORKSHOP IN GENERAL PRACTICE - PowerPoint PPT Presentation

1 / 38
About This Presentation
Title:

DIABETES WORKSHOP IN GENERAL PRACTICE

Description:

1962 : 1,000 citizens , 4% clinistix - oral GTT, 25%intolerant ... liver gluconeogenesis. gastric emptying. GLP1 agonist [glucose like peptide] ... – PowerPoint PPT presentation

Number of Views:130
Avg rating:3.0/5.0
Slides: 39
Provided by: mywebTi
Category:

less

Transcript and Presenter's Notes

Title: DIABETES WORKSHOP IN GENERAL PRACTICE


1
DIABETES WORKSHOP IN GENERAL PRACTICE
  • Dr John Rochford
  • GP Sharnbrook

2
Bedford Diabetes Survey
  • 1962 1,000 citizens ,
  • 4 clinistix -gt oral GTT, 25intolerant
  • 240 randomised Tolbutamide / placebo
  • 5 per annumm ? Diabetes
  • 20 world diabetes experts
  • lt 7.8 m mol diabetes absent
  • gt 11.1 m mol diabetes present

3
Diabetes Classification
  • 1936 Ainsworth
  • Insulin Dependent Diabetes IDDM
  • Non Insulin Dependent Diabetes NIDD
  • Type I or Type II
  • 1997 Type 1, 2, 3, 4, 5, 6,

4
UK epidemiology
  • England 2008
  • 2.5 million 4 ? 3 ? 90 type 2
  • Prevalence doubled 1991 ? 2003
  • North Bedfordshire
  • 1994 7,000
  • 2008 3.5 14,643
  • Sharnbrook Surgery
  • 1986 70 1.2
  • 2008 192 3.4

5
Why do we treat ?
  • ? life expectancy by 15 years
  • 80 die of macrovascular disease
  • ? healthcare costs by 3
  • ? HbA1c of 1
  • ? Fatal MI 17
  • ? CVA risk 37

6
Two trials
  • DCCT
  • 1,441 Type 1 patients , USA
  • Intensive pump v conventional treatment
  • ? retinopathy 70, ? neuropathy 64
  • ? cardiac pvd 41 , ? hypos 3 ? weight
  • UKPDS
  • 5,000 new Type 2 patients, UK
  • Intensive DM treatment eye 25 , renal 33
  • Intensive BP control ? macrovascular death

7
Complications
  • Macro vascular
  • Cardiac
  • Cerebro-vascular
  • Peripheral Vascular Disease
  • Micro Vascular
  • Retinal
  • Renal
  • Impotence
  • Peripheral neuropathy

8
Drug treatments BNF 6.1
  • Sulphonylureas ? insulin release
  • Biguanides ? periph glucose utilisatn
  • ? hepatic glucose
    production
  • Glitazones ? insulin resistance
  • Incretins ? insulin reponse to oral
    glucose
  • Alpha glucosidase delays starch absorpn
  • Insulin moves glucose into cells

9
Metformin
  • Doses 500 mg , 850 mg , SR , max 2g /d
  • .s/e nausea , vomiting, diarrhoea, wt
  • .c/I liver , CCF,
  • renal creat gt 150 / eGFR lt30

10
Sulphonylurea
  • Gliclizide , Glimepramide, Glipizide
  • Glibenclamide, Chlorpropamide
  • Prandial Glucose Regulators
  • Repaglanide , Nateglinide
  • s/e Hypo, weight
  • c/I severe liver / renal impairment

11
Glitazones
  • troglitazone Pioglitazone , Rosiglitazone
  • Triple therapy
  • s/e weight, fluid retention, fractures, GI,
    lipids,
  • c/i CCF, vascular disease, liver disease

12
Incretins
  • Incretin effect
  • ? glucose load in blood
  • ? liver gluconeogenesis
  • ? gastric emptying
  • GLP1 agonist glucose like peptide
  • DPP4 inhibitor DiPeptidyl Peptidase 4

13
Exanatide
  • Hospital initiation only at present
  • BMI gt 35 , HbA1c gt 7.5
  • 5-10 mcg daily sc 60 doses ac
  • Can add to Metformin / Sulphonylurea
  • ? weight, ? HbA1c by 1
  • s/e Nausea , dizzy, h/a, apetite,
    pancreatitis
  • c/i renal disease, glitazones, insulin

14
Sitagliptin / Vandagliptin
  • Single daily dose 100mg mg
  • Can add to Metformin / sulphonylurea
  • s/e GI disturbance, oedema , urti,
  • c/i severe renal disease

15
Insulin
  • Currently only in hospital in North Beds
  • blood glucose testing
  • Intensive lifestyle review
  • Weight gain
  • Insulin treated Type 2
  • Insulin regimes dose adjustment
  • 10 / 10 / 15 // 25
  • 25 / 30

16
Combination therapies
  • Underweight BMI lt 20
  • Sulphonylurea
  • 2nd line Insulin
  • Normal / over wt 20 25 / 25-35
  • Metformin
  • 2nd line Sulphonylurea
  • 3rd line sitagliptin
  • 4th line Glitazone / Exanetide
  • 5th line Insulin

17
Combination therapies
  • Obese BMI gt 35
  • Metformin
  • 2nd line Sulphonylurea
  • 3rd line exanetide / sitagliptin glitazone
  • 4th line Intensive lifestyle review
  • 5th line insulin

18
Annual cost of drugs
  • Metformin 2g / day 17
  • Gliclazide 320mg 35
  • Rosiglitazone 16 mg 482
  • Pioglitazone 45 mg 482
  • Glargine insulin 25 u 237
  • Sitagliptin 100 mg 434
  • Vidagliptin 100mg 414
  • Exanatide 20 mcg 830

19
Hypoglycaemia
  • Definition
  • Severe hypo
  • Symptoms
  • adrenergic
  • neuroglycopenic
  • Management
  • Oral treatment
  • Glucagon

20
B G T S
  • Testing frequency
  • Insulin
  • Tablets
  • Diet alone
  • Urine testing

21
(No Transcript)
22
Glucose Targets HbA1c
  • QoF 10.0 7.5
  • Old 7.0
  • NICE 6.5

23
Cholesterol
  • Cholesterol measurement
  • Diet
  • Drug therapy
  • Monitoring HDL LDL

24
Cholesterol Targets
  • QoF
  • total 5.0 LDL 3.0
  • NICE
  • total 4.0 LDL 2.0

25
Hypertension
  • Blood Pressure below
  • Q o F 150/90
  • Conventional 140/80
  • Renal disease 130/80
  • Proteinuria gt100g 120/80

26
Hypertension
  • Lifestyle
  • Weight
  • Waist circumference
  • Sodium
  • BP Measurement in surgery / at home

27
Hypertension
  • A B C D
  • A ACE inhibitors A2RB
  • B A2 blocker
  • C Calcium antagonists
  • D Diuretics
  • Other drugs
  • Beta or Alpha blockers
  • Centrally acting moxonidine , clonidine,
    methyl dopa
  • Spironolactone

28
Kidney Disease
  • Classification
  • Stage 1 eGFR gt90 ml/min/1.73m2
  • . 2 60 - 89
  • . 3a 45 - 59
  • . 3b 30 44
  • . 4 15 29
  • . 5 lt 15

29
Microalbuminuria testing
  • ACR albumen / creatinine ratio
  • Male gt 2.5
  • Female gt 3.5
  • Confirm by 2 of 3 pos EMU
  • Avoid
  • Smoking
  • Non steroidals
  • Excess weight
  • Lack of exercise

30
Microalbuminuria management
  • ACE / A2RB
  • Aspirin 75 mg
  • B P target lt 130/80
  • Diabetes control optimised HbA1c lt 6.5

31
Ongoing care
  • Retest every 12 months
  • if MAU , re test every 6 months
  • Refer
  • eGFR lt30 , CKD stage 4 / 5
  • ACR gt 70

32
CKD without diabetes
  • Routinely request eGFR with creatinine
  • eGFR lt 60 retest in 2/52
  • Test ACR on EMU preferable to PCR,
  • Re test ACR if gt 30
  • Dont test for protein with sticks
  • If ACR 30 70 dip test for haematuria

33
CKD without diabetes What next
  • ACR 30 70 no haematuria
  • BP lt 140/90 ACE / A2
  • Statins
  • Aspirin
  • FBC to see if Hb lt 11.0 if it is refer

34
CKD without diabetes Refer
  • ACR gt 70 / haematuria , renal u/s
  • Rapid decline of eGFR
  • gt 5 ml / yr
  • gt 10 ml in 5 yrs
  • On 4 hypertension drugs
  • CKD stage 4 or 5

35
Managing the patients
  • Running the clinic
  • Call recall system
  • Blood tests
  • Seeing the patients
  • Eye Screening
  • New patients
  • Follow up after diagnosis
  • Education - DESMOND

36
Metabolic syndrome
  • Global prev 16 UK 25
  • International Diabetes Federation
  • Central obesity waist gt 94 M / 80 F
  • Plus two of the following
  • fast glu gt 5.5,
  • TG gt 1.7,
  • HDL chol lt 1.03 M / 1.29 F
  • BP gt 130/85
  • Management wt loss, diet, exercise, BP, lipids

37
Pregnancy
  • Pre pregnancy counselling
  • Smoking folic acid 5mg
  • Diabetes control optimised
  • Gestational diabetes
  • Drugs
  • Metformin and insulin ok
  • Stop statins , ACE/A2

38
New local horizons
  • Can we make local care more effective ?
  • Do we need to send so many patients to the
    hospital ?
  • Do we need local Diabetes champions / GPwSI ?
Write a Comment
User Comments (0)
About PowerShow.com